While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.67. ABR value is precisely based on brokerage recommendations, where out of 3 brokerage recommendations 2 rate Caladrius Biosciences, Inc. stock a Strong Buy, 0 rate the stocks of the company a Buy, 1 rate Hold, 0 rate Sell and 0 recommend a Strong Sell.
Caladrius Biosciences, Inc., belongs to Healthcare sector and Biotechnology industry. The company’s Market capitalization is $31.46MB with the total Outstanding Shares of 18.60M. On 1-20-2021 (Wednesday), CLBS‘s stock construct a change of 150.92% in a total of its share price and finished its trading at 4.09.
CLBS Stocks 168.37% Far from 50 Day Moving Average
After a stumble in the market that brought CLBS to its low price for the period of the last 52 weeks, Caladrius Biosciences, Inc. was unable to take a rebound, for now settling with 289.52% of loss for the given period.
Having a look at past record, we’re going to look at various forwards or backwards shifting developments regarding CLBS. The firm’s shares rose 2.52% in the past five business days and grew 9.40% in the past thirty business days. In the previous quarter, the stock plunged -4.12% at some point. The output of the stock decreased -38.02% within the six-month closing period, while general annual output decreased -47.59%. The company’s performance is now positive at 13.99% from the beginning of the calendar year.
Earnings per Share Details of Caladrius Biosciences, Inc.
Lets a quick look at CLBS’s past reported and future predictions of growth using the EPS Growth. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end.
The company posted a value of $-12.40% as earning-per-share over the last full year, while a chance, will post $40.80% for the coming year. In-depth, if we analyze for the long-term EPS Growth, the out-come was 35.50% for the past five years and the scenario is totally different as the current prediction is 0 for the next five year.
P/S, P/E, P/C and P/B/ SMA50, SMA 200:
The price-to-sales is a valuation ratio that relates a company’s stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a company’s sales or taxes. As of now, CLBS has a P/S, P/E and P/B values of 0, 0 and 0.80 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.
Its P/Cash valued at 0.78. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stock’s price to its cash flow per share. Investors focus on the profitability proportions of the company that how the company performs at profitability side. Return on equity ratio or ROE is a significant indicator for prospective investors as they would like to see just how effectively a business is using their cash to produce net earnings.
Watching some historical volatility numbers on shares of Caladrius Biosciences, Inc. (CLBS) we can see that the 30 days volatility is presently 6.78%. The 7 days volatility is 6.52%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.
The company has a beta of Caladrius Biosciences, Inc. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.
As a return on equity, Caladrius Biosciences, Inc. (NASDAQ: CLBS) produces -28.00%. Because it would be easy and highly flexible, ROI measurement is among the most popular investment ratios. Executives could use it to evaluate the levels of performance on acquisitions of capital equipment whereas investors can determine that how the stock investment is better. The ROI entry for CLBS’s scenario is at 0. Another main metric of a profitability ratio is the return on assets ratio or ROA that analyses how effectively a business can handle its assets to generate earnings over duration of time. Caladrius Biosciences, Inc. (CLBS) generated -23.80% ROA for the trading twelve-month.
What do you mean by simple moving average (SMA)?
Based on a recent bid, its distance from 20 days simple moving average is 167.93%, and it has a distance of 118.92% from the 200 days simple moving average.
The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. The Company’s payout ratio was 0 and Price to free cash flow remained $0.